WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

• Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6)
• Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all

SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by the environmental non-profit CDP for leadership in corporate transparency and performance on water security, securing a place on the organization's annual "A List" for the second year.

According to CDP's scoring methodology, companies are evaluated on their awareness of environmental issues, management methods and advancements in environmental stewardship. Assessments are conducted across four levels that represent the steps a company moves through on its action journey: Disclosure (D-/D score), Awareness (C-/C score), Management (B-/B score), Leadership (A/A- score).

Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of "A" for Water Security, standing out among over 25,000 companies evaluated.

As a contributor to the United Nations Sustainable Development Goal 6 (SDG6), WuXi Biologics has adopted a systematic approach to enhance environment-friendly water management and help ensure the availability of water and sanitation for all. Various proactive measures regarding water are employed: measuring, avoiding, reducing and recycling. The company has set a target to reduce water consumption intensity by 30% by 2025 from the base year 2019. Reaffirming its dedication to good water stewardship and commitment to sustainable water management, the company launched a Water Excellence Stewardship (WES) program covering water governance, water balance, water quality, safe water/environmental and personal hygiene (WASH), and other material topics.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to be named once again on the CDP Water Security 'A' list, an acknowledgement that further inspires our steadfast dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide to fulfill ESG commitments, and jointly work with all stakeholders to promote responsible practices throughout the entire value chain."

As a participant of the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI) for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; merited an "A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.

About CDP

CDP is a global non-profit that runs the world's only independent environmental disclosure system. As the founder of environmental reporting, the organization believes in transparency and the power of data to drive change. Partnering with leaders in enterprise, capital, policy and science, CDP surfaces the information needed to enable Earth-positive decisions. It helped more than 24,800 companies and 1,100 cities, states and regions disclose their environmental impacts in 2024. Financial institutions with more than a quarter of the world's institutional assets use CDP data to help inform investment and lending decisions. Aligned with the ISSB's climate standard, IFRS S2, as its foundational baseline, CDP integrates best-practice reporting standards and frameworks in one place. The team is truly global, united by a shared desire to build a world where people, planet and profit are truly balanced.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

ESG
[email protected]

Media
[email protected]

SOURCE WuXi Biologics